Why I founded MedShadow
Suzanne Robotti on turning a family experience into patient advocacy.
Press Room
MedShadow’s coverage and commentary highlight our mission to provide science-based information, independent of pharmaceutical influence, to help people to make informed decisions about the RX and OTC medications they take. For media inquiries, contact Lisa Jaycox at press@medshadow.org.
FEATURED MEDIA
MedShadow Poll: Americans Want Prescription Drug Advertising Reform
Half of Americans support banning prescription drug advertising, one in five view its overall effect as harmful, and two-thirds say there are too many ads
WATCH MEDSHADOW
The stories people share
Selected social videos introduce our mission, advocacy, and investigations through the voices behind the work.
Why two generics can feel different
Emma Yasinski explains the quality questions behind a viral investigation.
Three recalls patients should know
Kaylei Fear breaks down the latest safety alerts in plain language.
In the press
Recent news
Recent coverage featuring MedShadow's work and experts.
Expand the complete media archive — or browse by year
Can the FDA Keep Up With the Peptide Boom?
As peptide use grows faster than research and regulation, MedShadow’s Suzanne Robotti warns that consumers may mistake increased legal access for proof that these products are safe or effective.
Pediatrics–What Are You Thinking about Generic Drugs?
MedShadow's Suzanne Robotti writes about how the the American Academy of Pediatrics is ignoring red flags on generic drug quality and bioequivalence, and asks, don't children deserve better?
Morning Briefing: Pharma and Tech News
Emma Yasinski's investigation for MedShadow into unregulated weight-loss products found widespread contamination with Tejocote Root, as cited in KFF's popular newsletter.
Shorty Awards: Investigating Generics
MedShadow's Investigating Generics series of articles, webinars, and survey named as a finalist for its creativity and effectiveness.
Characteristics of U.S. FDA Drug Recalls Involving Opioid Medications, 2002-2025
This paper analyzes over 20 years of FDA recall data and credits Emma Yasinski and MedShadow for "thoughtful inquiries regarding opioid supply safety that inspired the conception of the manuscript."
How a small journalism nonprofit is holding the largest pharma companies to account
MedShadow's Diane Salvatore explains our nonprofit investigative journalism approach, success with social media videos, and what's on the horizon for MedShadow's advocacy and editorial priorities.
ADHD Medication Quality, Oversight, and Reporting
MedShadow's Emma Yasinski explores the hidden complexities of medication safety, the ongoing ADHD medication shortage, and the vital role patients play in drug oversight.
Common painkillers cited as cause of misdiagnosed heart failure
Drugs like gabapentin can cause fluid retention, leading to symptoms that doctors may confuse for heart failure. MedShadow’s article on prescription cascades offers more information.
From Civil Rights Hubs to Pharmacy Deserts: What Pharmacy Closures Mean—And How You Can Take Action
Pharmacies provide essential care. The loss of a nearby pharmacy hurts the people who rely on it the most. An article in MedShadow’s Meet Me At the Medcart inspired this post.
US government issues recall for popular blood pressure medicine
Food and drug recalls are a fact of life. In this article, a MedShadow article is cited with an interviewee, Joey Mattingly, quoted about the drug recall process.
Episode 118: The Hidden Dangers in Your Medicine Cabinet
MedShadow’s Suzanne Robotti discusses drug trials, ADHD, and the importance of being your own health advocate.
Why Won’t MDs and Pharmacists Believe You When Generic Drugs Fail?
MedShadow’s webinar on Investigating Generic Drugs featured Joe Graedon, David Light, and Katherine Eban.
The Definitive Guide to Generic Drug Approval in the U.S.: From ANDA to Market Dominance
MedShadow’s Investigating Generics coverage is cited in this comprehensive report on the generic drug market in the U.S.
FDA Clinical Trial Inclusivity Guidelines Will Be Back
In this op-ed, MedShadow’s Suzanne Robotti argues that inclusivity guidelines at the FDA are “necessary.”
A Sickle Cell Drug That Was Hyped In Headlines Is Now Suspected Of Harming Patients
MedShadow’s Suzanne Robotti is quoted and advises that neutral language should be used for new drugs, rather than boosterish language like “miracle” or “game-changer.”
DES Daughters: A Medication My Mother Took Before I Was Born Will Affect Me for Life
MedShadow’s Suzanne Robotti shares her personal story about a drug that was given to millions of pregnant women with unintended side effects.
Women In Wellness: Five Lifestyle Tweaks That Will Help Support People’s Journey Towards Better Wellbeing
From mental health to physical well-being, women like Su Robotti are making significant strides in bringing about change, introducing innovative solutions, and setting new standards.
The FDA should withdraw approval of more than 400 tainted medicines
In this op-ed, MedShadow’s Suzanne Robotti argues that the FDA should have withdrawn 400 drugs from the market after learning they had received fraudulent testing data.
Open Letter to the FDA: You’re Protecting the Wrong People
An unnamed number of drugs on the market were approved based on potentially fraudulent testing and data. These medications may not be safe or effective, writes Suzanne Robotti.
Treatments for COPD, excessive sweating, and more
MedShadow Foundation’s article about the DEA’s schedule of drugs is cited in this round-up of drug and treatment news.
17 Unspoken Truths About Prescription Medication
Discover the untold truths of medication safety with MedShadow’s Suzanne Robotti.
An Attack on Patients’ Right to Informed Consent
In this op-ed, MedShadow’s Suzanne Robotti discusses claims that Merck failed to warn patients about the risk of an atypical femoral fracture from Fosamax.
Episode 56: Prescribed and Confused? Ask These 5 Key Medication Questions
Feeling powerless in the face of medication decisions? MedShadow’s Su Robotti's personal journey will surprise and inspire you.
From MedShadow
News releases
Announcements, research launches, award news, and organizational updates.
MedShadow Poll: Americans Want Prescription Drug Advertising Reform
Half of Americans support banning prescription drug advertising, one in five view its overall effect as harmful, and two-thirds say there are too many ads According to a new national MedShadow Foundation poll conducted by the Siena Research Institute, half of Americans (50%) support banning prescription drug advertisements. The poll also reveals a generational divide:
Read release ↗
MedShadow’s SSRIs Article, “Blunted Before They Can Bloom,” Wins Folio Award at Fair Media Council’s 45th Annual Folio Awards
MedShadow Foundation was recognized today at the Fair Media Council‘s 45th Annual Folio Awards Luncheon, held at the historic Garden City Hotel in New York. The award in the News Division – Mental Health Coverage category honored MedShadow’s Contributing Writer Peg Rosen, Head of Content Jessica DiGiacinto, Executive Director Diane Salvatore, and Founder Suzanne Robotti
Read release ↗MedShadow’s Investigating Generics Series Selected as a Finalist at the 18th Annual Shorty Awards
MedShadow Foundation has been shortlisted for the 18th Annual Shorty Awards for Investigating Generics in the Strategy and Engagement: On a Shoestring category, showcasing the creativity and effectiveness of its work in digital media. “Investigating Generics serves an urgent need in providing critical information to the public about the life-threatening quality breakdowns in the generic
Read release ↗
Redesigned MedShadow.org website provides improved ways to explore side effects and safety of medications
In response to demand, MedShadow has improved design, speed, and content organization for users New York, NY – December 15, 2025 – Today, the MedShadow Foundation unveiled a sleek and modern new look and improved functionality for its website, MedShadow.org, resulting in a superior user experience with intuitive navigation, faster search, new opportunities for engagement,
Read release ↗Working together
Featured partners
Organizations that help extend the reach of independent health journalism, research, and patient education.
Food as medicine, responsibly
Partnering on clear, evidence-led nutrition and medication information.
Visit Partner Site
Independent answers for patients
Sharing expert conversations about generics, side effects, and safer care.
Visit Partner SiteRecognition
Recent awards
Evidence-based journalism honored by leading media and healthcare programs.
Event galleryMedShadow staff, partners, and experts in the field.
2026
Mental Health Coverage
“Blunted Before They Can Bloom: SSRIs and Sexual Side Effects in Adolescents” — Peg Rosen, Jessica DiGiacinto, and Diane Salvatore.
READ THE WINNING WORK2026
Suzanne Robotti
Honored for advancing patient advocacy and improving the healthcare industry.
ABOUT THE HONOR2026
Investigating Generics
Series by Emma Yasinski et al., recognized for ambitious public-interest reporting.
VIEW THE ENTRYSpokespeople
Our experts
Staff and Health & Medical Advisory Panel members available for media interviews and background conversations.
Editorial leadership
Suzanne B. Robotti
Founder and President
Read bio ↗
Diane Salvatore
Executive Director
Read bio ↗
Jessica DiGiacinto
Head of Content
Read bio ↗
Emma Yasinski
Senior Investigative Reporter
Read bio ↗Health & Medical Advisory Panel
Beau Anderson
Ph.D.
Read bio ↗
Stefanie Ferreri
PharmD
Read bio ↗
Ritu Goel, M.D.
M.D.
Read bio ↗
Sara Rogers, PharmD.
PharmD
Read bio ↗
Lillie Rosenthal
D.O.
Read bio ↗Downloads
Media toolkit
Background information, updated logos, and resources for journalists and partners.
About MedShadow
Mission, audience, leadership, and impact at a glance.
DOWNLOAD PDF ↓
MedShadow logos
Full-color and reversed logo files for light and dark backgrounds.
Horizontal Blue JPG ↓ Square Blue, No Tagline JPG ↓ Horizontal White JPG ↓ Square White, No Tagline JPG ↓ Square Blue with Tagline JPG ↓
On deadline?
Talk with a MedShadow expert.
For interviews, background, permissions, or access to research and high-resolution assets, contact the press team.